Stevanato Group/$STVN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Stevanato Group
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.
Ticker
$STVN
Sector
Primary listing
NYSE
Employees
6,010
Headquarters
Piombino Dese, Italy
Website
Stevanato Group Metrics
BasicAdvanced
$5.4bn
33.76
$0.59
0.78
$0.06
0.31%
Price and volume
Market cap
$5.4bn
Beta
0.78
52-week high
$28.00
52-week low
$12.89
Average daily volume
304k
Dividend rate
$0.06
Financial strength
Current ratio
1.633
Quick ratio
1.104
Long term debt to equity
21.152
Total debt to equity
29.434
Dividend payout ratio (TTM)
10.42%
Interest coverage (TTM)
30.47%
Profitability
EBITDA (TTM)
334.195
Gross margin (TTM)
29.22%
Net profit margin (TTM)
11.75%
Operating margin (TTM)
17.20%
Effective tax rate (TTM)
26.85%
Revenue per employee (TTM)
$230,590
Management effectiveness
Return on assets (TTM)
5.27%
Return on equity (TTM)
9.59%
Valuation
Price to earnings (TTM)
33.759
Price to revenue (TTM)
3.906
Price to book
3.54
Price to tangible book (TTM)
3.75
Price to free cash flow (TTM)
-384.104
Free cash flow yield (TTM)
-0.26%
Free cash flow per share (TTM)
-0.052
Dividend yield (TTM)
0.31%
Forward dividend yield
0.31%
Growth
Revenue change (TTM)
6.99%
Earnings per share change (TTM)
11.10%
3-year revenue growth (CAGR)
6.02%
3-year earnings per share growth (CAGR)
-1.99%
What the Analysts think about Stevanato Group
Analyst ratings (Buy, Hold, Sell) for Stevanato Group stock.
Stevanato Group Financial Performance
Revenues and expenses
Stevanato Group Earnings Performance
Company profitability
Stevanato Group News
AllArticlesVideos
Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries
Business Wire·3 days ago
Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026
Business Wire·2 weeks ago
Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.